Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12803268 | 0.88 | KLKB1 (0.49) | KMT2ATP53LMNATHRBMAPK1 | |
| SCHEMBL12803747 | 0.88 | KMT2A (0.47) | CNR1KMT2ATP53LMNATHRB | |
| Hydrochloric Acid SCHEMBL1981812 | 0.87 | KLKB1 (0.48) | KMT2ATP53LMNATHRBMAPK1 | |
| SCHEMBL12803421 | 0.87 | KLKB1 (0.48) | KMT2ATP53LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL12803552 | 0.86 | KLKB1 (0.47) | KMT2ATP53LMNAMAPK1 | |
| SCHEMBL12597695 | 0.83 | NAMPT (0.49) | KMT2ATP53KDM4E | |
| Methylamine SCHEMBL3780610 | 0.83 | MALT1 (0.44) | CNR1SCN2ASCN10AKMT2ALMNA | |
| SCHEMBL1989986 | 0.83 | LMNA (0.41) | CNR1KMT2ATP53LMNAHTT | |
| SCHEMBL1981617 | 0.82 | PIK3CD (0.43) | KMT2ATP53LMNA | |
| SCHEMBL3790086 | 0.80 | TP53 (0.44) | TP53LMNAHTTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513059-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252806-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2012-10-04 | — | — | US | disclosed |
| WO-2011075383-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252806-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | CNR1 4522/4885SCN2A 3258/4885SCN10A 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.